特发性肺纤维化:从症状识别到诊断的诊疗路径及疾病负担的医患视角
本研究基于法国、德国、日本和美国的真实世界数据,评估特发性肺纤维化(IPF)从症状识别到治疗的诊疗路径。244名医生报告了1249名患者的数据,其中739名患者自报数据。结果显示诊断延迟0.8至2.0年,治疗启动进一步延迟,患者报告的生活质量低,住院率高。
要点
- IPF患者从症状出现到诊断延迟0.8至2.0年,治疗启动进一步延迟。
- 诊断前患者平均接受7-10项临床检查,抗纤维化药物使用从57%(2016年)增至69%(2019年)。
- 12个月住院率从24%(日本)至64%(美国),患者报告生活质量低(EQ-5D VAS均值61.7/100)。
核心结论
- IPF患者经历显著的诊断和治疗延迟,需要更有效的治疗和管理以减轻疾病负担。
研究设计与样本
- 定量、时点数据收集自Adelphi IPF II疾病特定项目,来自法国、德国、日本和美国。
- 244名医生报告1249名患者数据,其中739名患者自报数据,医患数据匹配。
主要发现
- 诊断延迟为0.8年(德国)至2.0年(日本),治疗启动进一步延迟。
- 所有国家中,患者比医生更常报告症状。
- 诊断前患者平均接受7-10项临床检查。
- 抗纤维化药物使用从57%(2016年)增至69%(2019年)。
- 仅50%的中度/重度IPF患者对治疗满意。
临床怎么用
- 临床医生应提高对IPF症状的识别,减少诊断延迟。
- 考虑抗纤维化治疗的使用和患者满意度,优化管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease that requires ongoing care and is associated with considerable socioeconomic burden. We evaluated the IPF care pathway from symptom recognition to treatment. We describe the impact of IPF on healthcare resource use (HCRU), quality of life (QoL) and work impairment, and report differences in patient and physician perspectives using real-world data from France, Germany, Japan and the United States. METHODS: Quantitative, point-in-time data were collected as part of the Adelphi IPF II Disease Specific Programme™. Physician-reported data (patient demographics, medical history, diagnoses, treatment) were matched to patient-reported data (HCRU, QoL, work impairment). HCRU was measured as physician visits and hospitalizations. QoL and work impairment were measured using the EuroQol-5 Dimensions (EQ-5D) and Work Productivity and Activity Impairment questionnaires. RESULTS: Overall, 244 physicians reported data on 1249 patients, 739 of whom self-reported data. Diagnostic delays of 0.8 (Germany) to 2.0 (Japan) years after symptom onset were reported; treatment initiation was further delayed. In all countries, patients more often reported symptoms in the survey than did their physicians. On average, patients underwent 7-10 clinical tests before diagnosis. Antifibrotic use increased from 57% (2016) to 69% (2019); only 50% of patients with moderate/severe IPF were satisfied with their treatment. The 12-month hospitalization rates were 24% (Japan) to 64% (United States). Patients reported low QoL (mean EQ-5D visual analogue scale: 61.7/100). CONCLUSION: Patients with IPF experience considerable diagnostic and treatment delays. More effective therapies and management are needed to reduce the disease burden.
引用
- Lancaster L, Bonella F, Inoue Y, et al. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology. 2021. PMID: 34611971. doi:10.1111/resp.14154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。